Molecular research in urology 2014: Update on PET/MR imaging of the prostate

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13401-13405

  Wetter, Axel ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Multi parametric MR imaging; PET MRI; Prostate

Indexed keywords

HUMAN; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; RADIOGRAPHY; RESEARCH; UROLOGY;

HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RESEARCH; UROLOGY;

EID: 84905643355     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813401     Document Type: Letter

References (20)

1. Hricak, H.; Williams, R.D.; Spring, D.B.; Moon, K.L.; Hedgcock, M.W.; Watson, R.A.; Crooks, L.E. Anatomy and pathology of the male pelvis by magnetic resonance imaging. Am. J. Roentgenol. 1983, 141, 1101-1110.
2. Yu, K.K.; Hricak, H.; Alagappan, R.; Chernoff, D.M.; Bacchetti, P.; Zaloudek, C.J. Detection of extracapsular extension ofprostate carcinoma with endorectal and phased-array coil MR imaging: Multivariate feature analysis. Radiology 1997, 202, 697-702.
3. Engelbrecht, M.R.; Huisman, H.J.; Laheij, R.J.F.; Jager, G.J.; van Leenders, G.J.L.H.; Hulsbergen-van de Kaa, C.A.; de la Rosette, J.J.M.C.H.; Blickman, J.G.; Barentsz, J.O. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003, 229, 248-254.
4. Fütterer, J.J.; Heijmink, S.W.; Scheenen, T.W.J.; Veltman, J.; Huisman, H.J.; Vos, P.; Hulsbergen-van de Kaa, C.A.; Witjes, J.A.; Krabbe, P.F.M.; Heerschap, A.; et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006, 241, 449-458.
5. Kim, C.K.; Park, B.K.; Lee, H.M.; Kwon, G.Y. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: Preliminary results. Investig. Radiol. 2007, 42, 842-847
6. Delongchamps, N.B.; Beuvon, F.; Eiss, D.; Flam, T.; Muradyan, N.; Zerbib, M.; Peyromaure, M.; Cornud, F. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis. 2011, 14, 232-237
7. Oto, A.; Kayhan, A.; Jiang, Y.; Tretiakova, M.; Yang, C.; Antic, T.; Dahi, F.; Shalhav, A.L.; Karczmar, G.; Stadler, W.M. Prostate cancer: Differentiation ofcentral gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010, 257, 715-723.
8. Kitajima, K.; Kaji, Y.; Fukabori, Y.; Yoshida, K.; Suganuma, N.; Sugimura, K. Prostate cancer detection with 3 T MRI: Comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J. Magn. Reson. Imaging 2010,31, 625-631.
9. Murphy, G.; Haider, M.; Ghai, S.; Sreeharsha, B. The expanding role of MRI in prostate cancer. Am. J. Roentgenol. 2013, 201, 1229-1238.
10. Barentsz, J.O.; Richenberg, J.; Clements, R.; Choyke, P.; Verma, S.; Villeirs, G.; Rouviere, O.; Logager, V.; Futterer, J.J. ESUR prostate MR guidelines 2012. Eur. Radiol. 2012, 22, 746-757.
11. Bauman, G.; Belhocine, T.; Kovacs, M.; Ward, A.; Beheshti, M.; Rachinsky, I. 18 F-Fluorocholine for prostate cancer imaging: A systematic review of the literature. Prostate Cancer Prostatic Dis. 2012, 15, 45-55.
12. 18F choline positron emission tomography/magnetic resonance imaging of the prostate: Initial results. Investig. Radiol. 2013, 48, 256-262.
13. Wetter, A.; Lipponer, C.; Nensa, F.; Heusch, P.; Rubben, H.; Altenbernd, J.-C.; Schlosser, T.; Bockisch, A.; Poppel, T.; Lauenstein, T.; et al. Evaluation of the PET component of simultaneous [18F] choline PET/MRI in prostate cancer: Comparison with [18F] choline PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 79-88.
14. 18C] choline PET/MR with PET/CT in patients with prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 1488-1499.
15. Hartenbach, M.; Hartenbach, S.; Bechtloff, W.; Danz, B.; Kraft, K.; Klemenz, B.; Sparwasser, C.; Hacker, M. Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: A prospective diagnostic trial. Clin. Cancer Res. 2014, 20, 3244-3255.
16. 18F-choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: Preliminary results. Biomed. Res. Int. 2014, 2014, 103718.
17. 18F-fluorcholine PET/MRI for prostate cancer imaging. Eur. J. Nucl. Med. Mol. Imaging 2014, doi:10.1007/s00259-014-2786-7.
18. 18F] choline PET/MRI: Combined SUV and ADC analysis. Ann. Nucl. Med. 2014, 28, 405-410.
19. 18Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humansand first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 486-495.
20. 68Ga]-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: Initial experience. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 887-897.